04 September 2019
Visiongain has launched a new pharma report Blood Screening Market Forecast 2019-2029: By Technology (NAT, ELISA, CLIA, NGS, Western Blotting) & By Product (Reagents, Instruments) Segments.
The growth of the global blood screening market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Moreover, there is ever increasing demand for blood screening tests due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Also, governments across the countries are in process to mandates testing all donated blood for several viruses.
Blood donation requires the blood to be free from disease causing agents namely HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). This is done to decrease the chances of transfusion-transmitted contaminations (TTIs).
With continuous technological advancement in this segment, especially the U.S. FDA approved next-generation sequencing (NGS) technology in 2013 has made the blood screening cheaper and faster than previous DNA analysis methods has done well for the industry. The worldwide blood screening market is witnessing technological advancements with respect to devices and utilities involved in blood donation centres and doctor’s facilities for the screening of different TTIs.
Leading companies featured in the report include Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary Of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary Of Danaher Corporation), Becton, Dickinson And Company.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.